Indian pharma well positioned despite tariff threats, says Sandip Sabharwal

​Longer term, if the issues are not resolved, then for companies who are majority exports to the US there could be some issues. So, some adjustment of valuations are happening because of a potential threat, although small, at some stage.

More To Explore

FPIs withdraw Rs 48,056 cr from D-St in Oct

Foreign investors withdrew significant funds from Indian equities in October amid concerns over inflation and crude oil prices. Despite this, there were signs of moderation